Avita Medical, Inc. income statement AVHHL

In fiscal 2025, which ended Dec 31, 2025, Avita Medical, Inc. reported revenue of $70.9 million, up 10.9% from the year before. It recorded a net loss of $48.6 million. The operating loss came to $42.5 million, an operating margin of -60.0%. Diluted earnings per share were -$1.74. Over the twelve months ended Sep 30, 2026, revenue was $83.8 million and the net loss was $36.1 million. Across the 6 fiscal years shown, revenue grew from $14.3 million in fiscal 2020 to $70.9 million in fiscal 2025, about 37.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
Revenue
84
+17.0%
71
+10.9%
64
+27.4%
50
+45.7%
34
+17.8%
29
+104.9%
14
Cost of revenue
15
+26.9%
13
+40.7%
9
+16.9%
8
+28.8%
6
+1.5%
6
+100.1%
3
Gross profit
70
+15.0%
59
+6.6%
55
+30.2%
42
+49.3%
28
+21.9%
23
+106.2%
11
Research and development
21
+5.5%
21
+2.4%
20
-2.2%
21
+50.3%
14
-6.5%
15
+61.7%
9
Selling, general and administrative
77
-6.5%
81
-11.9%
91
+39.3%
66
+45.1%
45
+22.1%
37
-23.9%
49
Operating expenses
98
-4.2%
101
112
—
—
—
—
Operating income
-29
+31.8%
-43
+24.8%
-57
-32.7%
-43
-55.1%
-28
-3.6%
-27
+37.8%
-43
Interest expense
6
+11.2%
5
-6.7%
5
+369.0%
1
+7043.8%
0
-27.3%
0
-33.3%
0
Foreign currency gain (loss)
-0
-73.3%
-0
+19.0%
-0
+43.2%
-0
-143.5%
0
+137.3%
-0
-3157.1%
-0
Other non-operating income (expense)
-2
-26.4%
-1
-736.8%
0
-98.1%
8
—
—
—
Pretax income
-36
+25.7%
-49
+21.4%
-62
-75.0%
-35
-32.6%
-27
-0.3%
-27
+36.8%
-42
Income tax
0
+48.9%
0
-79.6%
0
-18.2%
0
+83.3%
0
-5.3%
0
+850.0%
0
Net income
-36
+25.6%
-49
+21.4%
-62
-74.8%
-35
-32.7%
-27
-0.3%
-27
+36.8%
-42
Basic EPS
-1.18
+34.9%
-1.74
+27.2%
-2.39
-70.7%
-1.40
-230.8%
1.07
-8.5%
1.17
-43.5%
2.07
Diluted EPS
-1.18
+34.9%
-1.74
+27.2%
-2.39
-70.7%
-1.40
-230.8%
1.07
-8.5%
1.17
-43.5%
2.07
Weighted average shares, basic
31
+14.3%
28
+7.6%
26
+2.2%
25
+1.3%
25
+10.3%
23
+11.7%
20
Weighted average shares, diluted
31
+14.3%
28
+7.6%
26
+2.2%
25
+1.3%
25
+10.3%
23
+11.7%
20
Other measures
Depreciation and amortization
3
+22.8%
2
+108.4%
1
+78.2%
1
+11.3%
1
-20.6%
1
+53.8%
0
EBITDA
-26
+34.6%
-40
+27.5%
-55
-32.0%
-42
-56.0%
-27
-4.3%
-26
+38.8%
-42
Interest coverage
-5.11x
-8.50x
-10.56x
-37.32x
-1,719.06x
-1,206.36x
-1,293.30x
Margins
Gross margin
83.18%
82.98%
86.33%
84.48%
82.45%
79.65%
79.16%
Operating margin
-34.22%
-60.01%
-88.57%
-85.07%
-79.91%
-90.79%
-299.23%
Pretax margin
-42.99%
-68.53%
-96.71%
-70.43%
-77.36%
-90.81%
-294.65%
Profit margin
-43.08%
-68.55%
-96.79%
-70.56%
-77.47%
-90.94%
-294.68%
EBITDA margin
-31.21%
-56.70%
-86.81%
-83.81%
-78.26%
-88.34%
-295.97%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
RCEL (Nasdaq), AVHHL (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Valencia, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1762303
Former names
Avita Therapeutics, Inc. (until Dec 10, 2020); Avita Medical, Ltd. (until Jun 30, 2020)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.